X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13142) 13142
Magazine Article (65) 65
Book / eBook (6) 6
Book Chapter (5) 5
Conference Proceeding (5) 5
Newspaper Article (2) 2
Publication (2) 2
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9497) 9497
piperidines - therapeutic use (8252) 8252
male (6707) 6707
female (5181) 5181
animals (4694) 4694
piperidines - pharmacology (4237) 4237
middle aged (3163) 3163
adult (2943) 2943
pharmacology & pharmacy (2876) 2876
aged (2656) 2656
rats (2073) 2073
piperidines - adverse effects (2040) 2040
piperidines - administration & dosage (2012) 2012
mice (1634) 1634
dose-response relationship, drug (1495) 1495
neurosciences (1449) 1449
indans - therapeutic use (1426) 1426
treatment outcome (1408) 1408
double-blind method (1385) 1385
psychiatry (1148) 1148
cholinesterase inhibitors - therapeutic use (1024) 1024
alzheimer disease - drug therapy (1020) 1020
clinical trials as topic (963) 963
donepezil (921) 921
time factors (899) 899
clinical neurology (877) 877
double-blind (842) 842
rats, sprague-dawley (802) 802
adolescent (785) 785
disease models, animal (774) 774
pyrazoles - pharmacology (761) 761
piperidines - pharmacokinetics (727) 727
aged, 80 and over (721) 721
oncology (718) 718
analysis (690) 690
alzheimer's disease (681) 681
drug therapy (645) 645
piperidines - chemistry (622) 622
drug therapy, combination (601) 601
efficacy (588) 588
research (573) 573
pyrazoles - therapeutic use (562) 562
rats, wistar (559) 559
piperidines (554) 554
nootropic agents - therapeutic use (543) 543
dementia (532) 532
administration, oral (529) 529
care and treatment (523) 523
receptor, cannabinoid, cb1 - antagonists & inhibitors (493) 493
remifentanil (491) 491
medicine, general & internal (485) 485
cisapride (484) 484
pharmacology/toxicology (484) 484
anesthesiology (482) 482
biochemistry & molecular biology (476) 476
medicine & public health (473) 473
cancer (464) 464
brain (463) 463
pyrimidines - therapeutic use (455) 455
schizophrenia - drug therapy (448) 448
pharmacology (447) 447
alzheimers-disease (445) 445
pharmacokinetics (441) 441
chemistry, medicinal (433) 433
expression (431) 431
drug interactions (428) 428
mice, inbred c57bl (427) 427
rodents (422) 422
prospective studies (419) 419
protein kinase inhibitors - therapeutic use (419) 419
child (416) 416
antineoplastic agents - therapeutic use (414) 414
research article (413) 413
diabetes mellitus, type 2 - drug therapy (406) 406
safety (404) 404
randomized controlled trials as topic (400) 400
health aspects (399) 399
pyrroles - therapeutic use (391) 391
inhibition (388) 388
activation (383) 383
clinical trials (382) 382
young adult (381) 381
hypoglycemic agents - therapeutic use (376) 376
blood pressure - drug effects (375) 375
rivastigmine (375) 375
apoptosis (372) 372
neurology (370) 370
cell line, tumor (357) 357
antipsychotic agents - therapeutic use (352) 352
endocrinology & metabolism (352) 352
therapy (352) 352
drugs (351) 351
biomedicine (350) 350
pyridines - therapeutic use (348) 348
surgery (341) 341
drug administration schedule (339) 339
risk factors (334) 334
rat (332) 332
analysis of variance (330) 330
in vitro techniques (329) 329
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11961) 11961
German (389) 389
French (297) 297
Japanese (206) 206
Italian (126) 126
Spanish (116) 116
Russian (99) 99
Chinese (67) 67
Polish (56) 56
Portuguese (46) 46
Czech (29) 29
Danish (23) 23
Dutch (13) 13
Norwegian (12) 12
Hungarian (11) 11
Romanian (8) 8
Swedish (6) 6
Slovak (5) 5
Finnish (3) 3
Hebrew (3) 3
Bulgarian (2) 2
Serbian (2) 2
Turkish (2) 2
Afrikaans (1) 1
Croatian (1) 1
Korean (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 496 - 503
Summary In March, 2010, a group of breast cancer experts met to develop a consensus statement on breast cancer prevention, with a focus on medical and therapeutic interventions... 
Hematology, Oncology and Palliative Medicine | ZOLEDRONIC ACID | SURGICAL ADJUVANT BREAST | ONCOLOGY | STATIN USE | LOW-DOSE TAMOXIFEN | RANDOMIZED-TRIAL | FOLLOW-UP | RISK | BOWEL PROJECT | POSTMENOPAUSAL WOMEN | GENOME-WIDE ASSOCIATION | Thiophenes - therapeutic use | Metformin - therapeutic use | Raloxifene Hydrochloride - therapeutic use | Humans | Selective Estrogen Receptor Modulators - adverse effects | Tetrahydronaphthalenes - therapeutic use | Pyrrolidines - therapeutic use | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Estrogen Receptor Modulators - therapeutic use | Retinoids - therapeutic use | Selective Estrogen Receptor Modulators - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Female | Aromatase Inhibitors - therapeutic use | Estrogen Receptor Modulators - adverse effects | Anticarcinogenic Agents - therapeutic use | Triazoles - therapeutic use | Premenopause | Anastrozole | Consensus Development Conferences as Topic | Breast Neoplasms - prevention & control | Fenretinide - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Piperidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Tamoxifen - therapeutic use | Androstadienes - therapeutic use | Expert Testimony | Norpregnenes - therapeutic use | Nitriles - therapeutic use | COX-2 inhibitors | Care and treatment | Aspirin | Oncology, Experimental | Menopause | Phosphonates | Breast cancer | Retinoids | Research | Tamoxifen | Prevention | Analysis | Health aspects | Cancer
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2019, Volume 80, Issue 4, pp. 1029 - 1072
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 06/2018, Volume 2018, Issue 6, p. CD006332
Background Opioid‐induced bowel dysfunction (OIBD) is characterised by constipation, incomplete evacuation, bloating, and gastric reflux. It is one of the... 
Quaternary Ammonium Compounds | Intestinal Diseases | Oxycodone | Receptors, Opioid, mu | Palliative Care | Palliative and supportive care | Naltrexone | Gastrointestinal | 2019 4. Palliative, supportive, frailty | Nalbuphine | Neoplasms | Randomized Controlled Trials as Topic | Narcotic Antagonists | Symptomatic relief | Naloxone | Piperidines | Child health | Opioid‐Related Disorders | Medicine General & Introductory Medical Sciences | Palliative & other supportive care | Constipation | Defecation | Gastrointestinal Agents | Cancer | Piperidines [therapeutic use] | EFFICACY | SAFETY | Humans | GUIDELINES | Gastrointestinal Agents [therapeutic use] | Intestinal Diseases [chemically induced; drug therapy] | MEDICINE, GENERAL & INTERNAL | Receptors | SUBCUTANEOUS METHYLNALTREXONE | Constipation [chemically induced; drug therapy] | PARALLEL-GROUP | Nalbuphine [therapeutic use] | mu [antagonists & inhibitors] | Naloxone [therapeutic use] | INDUCED CONSTIPATION | Opioid-Related Disorders [drug therapy] | Naltrexone [analogs & derivatives; therapeutic use] | Opioid | Quaternary Ammonium Compounds [therapeutic use] | PROLONGED-RELEASE TABLETS | Defecation [drug effects] | PAIN | Narcotic Antagonists [therapeutic use] | DOUBLE-BLIND | ADVANCED ILLNESS | Naltrexone - analogs & derivatives | Naltrexone - therapeutic use | Opioid-Related Disorders - drug therapy | Intestinal Diseases - chemically induced | Male | Neoplasms - complications | Nalbuphine - therapeutic use | Female | Constipation - drug therapy | Oxycodone - adverse effects | Oxycodone - therapeutic use | Defecation - drug effects | Quaternary Ammonium Compounds - therapeutic use | Intestinal Diseases - drug therapy | Narcotic Antagonists - adverse effects | Naloxone - therapeutic use | Receptors, Opioid, mu - antagonists & inhibitors | Constipation - chemically induced | Narcotic Antagonists - therapeutic use | Piperidines - therapeutic use | Naloxone - adverse effects | Gastrointestinal Agents - therapeutic use | Naltrexone - adverse effects
Journal Article
European heart journal, ISSN 1522-9645, 2015, Volume 36, Issue 34, pp. 2288 - 2296
Journal Article
Diabetes & metabolism, ISSN 1262-3636, 2012, Volume 38, Issue 2, pp. 89 - 101
Abstract Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes. Direct comparisons with active glucose-lowering... 
Internal Medicine | Endocrinology & Metabolism | Linagliptine | Sitagliptin | Type 2 diabetes mellitus | Review | Clinical trial-DPP-4 inhibitor | Vildagliptine | Saxagliptine | Diabète de type 2 | Inhibiteur de la DPP-4 | Alogliptin | Sitagliptine | Linagliptin | Vildagliptin | Alogliptine | Revue générale | Essai clinique | Saxagliptin | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | INITIAL COMBINATION THERAPY | RENAL IMPAIRMENT | DRUG-NAIVE PATIENTS | ADD-ON THERAPY | IMPROVES GLYCEMIC CONTROL | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | METFORMIN THERAPY | WEIGHT-GAIN | ELDERLY-PATIENTS | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Glycated Hemoglobin A - drug effects | Male | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Adamantane - therapeutic use | Female | Weight Gain - drug effects | Purines - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Uracil - therapeutic use | Clinical Trials as Topic | Diabetes Mellitus, Type 2 - blood | Piperidines - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - therapeutic use | Uracil - analogs & derivatives
Journal Article